| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD40 |
| Uniprot No | P25942 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-193aa |
| 氨基酸序列 | EPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDT WNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCV LHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETK DLVVQQAGTNKTDVVCGPQDRLR |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD40重组蛋白的3篇示例性参考文献(注：文献信息为假设性示例，仅供格式参考)：
---
1. **标题**：*Recombinant human CD40 ligand protein activates human B lymphocytes via CD40 signaling pathway*
**作者**：Smith A, et al.
**摘要**：本研究通过大肠杆菌系统表达并纯化了功能性人源CD40重组配体蛋白(rhCD40L)，证实其能有效激活体外培养的人B细胞，促进其增殖及抗体分泌，为免疫调节治疗提供实验依据。
---
2. **标题**：*Structural characterization of a soluble CD40 receptor-protein fusion and its antitumor efficacy in vivo*
**作者**：Li J, et al.
**摘要**：作者构建了可溶性CD40受体-Fc融合蛋白，解析其晶体结构并证明其通过阻断CD40/CD40L通路抑制肿瘤微环境中T细胞耗竭，在结肠癌小鼠模型中显著减缓肿瘤生长。
---
3. **标题**：*CD40-targeted recombinant protein vaccine enhances antigen-specific T cell responses in non-human primates*
**作者**：Wang Y, et al.
**摘要**：开发了一种基于CD40靶向的重组蛋白疫苗载体，通过在恒河猴模型中展示其可增强抗原呈递细胞对HIV抗原的摄取，并显著提升抗原特异性T细胞免疫应答。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词“recombinant CD40 protein”或“CD40 ligand expression”，筛选近年高引论文。
CD40 recombinant protein is a genetically engineered form of the CD40 molecule, a critical cell surface receptor belonging to the tumor necrosis factor receptor (TNFR) superfamily. Naturally expressed on antigen-presenting cells (APCs) such as B cells, dendritic cells, and macrophages, CD40 interacts with its ligand CD40L (CD154) on T cells to mediate bidirectional signaling. This interaction is pivotal for adaptive immune responses, including B cell activation, antibody class switching, germinal center formation, and T cell priming. Dysregulation of CD40-CD40L signaling is implicated in autoimmune diseases, cancer, and immunodeficiency.
Recombinant CD40 proteins are typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. They may be designed as soluble monomers or fused with Fc domains to enhance stability and mimic membrane-bound forms. Researchers utilize these proteins to study CD40 signaling pathways, modulate immune responses in vitro or in vivo, and develop therapeutic strategies. For instance, CD40 agonists are explored in cancer immunotherapy to activate APCs and amplify antitumor immunity, while antagonists may suppress harmful inflammation in autoimmune conditions.
In therapeutics, CD40-targeting biologics (e.g., monoclonal antibodies, recombinant ligands) are being tested in clinical trials for malignancies, chronic infections, and autoimmune disorders. The recombinant protein’s ability to "bridge" innate and adaptive immunity makes it a versatile tool in vaccine development and immune tolerance research. However, challenges remain in balancing efficacy with off-target effects, as sustained CD40 activation can trigger cytokine storms or unintended cell proliferation. Ongoing studies aim to optimize dosing and delivery systems to harness its immunomodulatory potential safely.
×
